BASF shares have been a standout performer this year, rallying over 20% since January to trade around €54.72. Yet this impressive run is showing signs of fatigue as the stock approaches a critical technical and fundamental juncture. The coming days will test whether the chemical giant’s aggressive restructuring can justify its elevated valuation.
Investors face a decisive double-header on April 30th. The annual shareholder meeting in Mannheim coincides with the release of first-quarter results, creating a pivotal moment for the stock. Shareholders will vote on the formal carve-out of the Agricultural Solutions business, a key step toward a planned standalone stock market listing by 2027. They are also set to approve a stable dividend of €2.25 per share, distributing nearly €1.98 billion from retained earnings.
Operationally, the company is fighting margin pressure on multiple fronts. Management has implemented significant price increases, demanding up to 30% more for certain cleaning products in Europe and raising prices for plastic additives by as much as 20%. These moves are part of a broader effort to offset persistent headwinds, including sluggish demand from the automotive and construction industries.
A weak US dollar presents another challenge, with the currency effect alone potentially depressing first-quarter operating profit by up to €200 million. In response, BASF is tightening its belt further. The cost-saving target for 2026 has been raised to €2.3 billion annually, up from the original goal of €2.1 billion. The company has already realized €1.7 billion in savings through the end of 2025.
Should investors sell immediately? Or is it worth buying BASF?
The fundamental picture leaves analysts deeply divided. With the stock trading at 16 times estimated 2026 earnings, some see a premium price for a cyclical chemicals player. Barclays maintains an “Underweight” rating with a €40 price target, citing high raw material dependency and a low free cash flow yield of 1.4%. Kepler Cheuvreux recently cut its target to €54.
Other banks are more optimistic. Goldman Sachs holds a “Buy” recommendation with a €63 target, praising the company’s structural cost levers. Deutsche Bank upgraded the stock to “Buy” with a €55 target, suggesting BASF could benefit from geopolitical uncertainties. In a separate business note, the company is exploring legal avenues in the U.S. to reclaim paid tariffs following a Supreme Court ruling, though CFO Dirk Elvermann notes the direct financial impact is limited as 80-90% of products sold in North America are produced locally.
Technically, the rally paused just shy of a major hurdle. After hitting a yearly high of €54.70 on April 10th, the stock retreated from resistance near €55. The pullback has eased overbought conditions, with the Relative Strength Index (RSI) cooling to a more neutral 43.3. Management’s full-year outlook adds to the cautious tone, forecasting 2026 EBITDA between €6.2 and €7.0 billion. Even the top end of that range falls just short of the €7.02 billion consensus expectation.
The upcoming shareholder votes and quarterly report will provide concrete evidence on whether the strategic price hikes and accelerated savings can effectively counterbalance the significant currency and demand challenges. The market’s verdict on BASF’s ambitious transformation is imminent.
Ad
BASF Stock: Buy or Sell?! New BASF Analysis from April 14 delivers the answer:
The latest BASF figures speak for themselves: Urgent action needed for BASF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 14.
BASF: Buy or sell? Read more here...
